Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

But there are facts, law and precedent on point, which are worth examining. First, we can start with 23andMe’s privacy statement, which is—to their credit—strong. In general, data can be ...

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million.